國家衛生研究院 NHRI:Item 3990099045/9625
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 910668      線上人數 : 854
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9625


    題名: Searching for a CYP17 inhibitor without cardiovascular side effects
    作者: Li, LA;Lin, TC;Cheng, LC;Lin, CJ;Wang, CJ
    貢獻者: National Institute of Environmental Health Sciences
    摘要: Question: CYP17 inhibitors have been used as androgen-depleting drugs for androgen-dependent diseases such as advanced prostate cancer. However, inhibition of the 17α-hydroxylase and 17,20-lyase activities of CYP17 by current inhibitors leads to elevation of corticosteroid production, which increases risk of cardiovascular diseases. There is a need to develop a new CYP17 inhibitor without cardiovascular side effects. Methods: Polyphenols resemble to steroids in structure. In this study, we explore the possible application of natural and synthetic polyphenols in CYP17 blockage using human adrenocortical H295R cells as a model. Results: Resveratrol is the most potent CYP17 inhibitor among the examined polyphenols. The value of IC50 is approximately 4 μM. Resveratrol also inhibits CYP21 but to a lesser extent as compared with CYP17. Because the 21α-hydroxylase activity of CYP21 is indispensable for corticosteroid biosynthesis, the dual inhibition of CYP17 and CYP21 by resveratrol prevents corticosteroid elevation following CYP17 blockage. Resveratrol inhibits CYP17 and CYP21 mainly at the level of enzyme activity rather than enzyme abundance and cytochrome P450 electron transfer. Daidzein inhibits 3βHSD2 (3β-hydroxysteroid dehydrogenase type II) in addition to CYP17 and CYP21. Therefore, dehydroepiandrosterone accumulation is accompanied with androgen biosynthetic impairment under daidzein treatment. On the other hand, androgen and cortisol secretion is increased or remains normal under α-naphthoflavone and β-naphthoflavone treatments. Conclusion: Our findings suggest a potential application of resveratrol in androgen deprivation therapy.
    日期: 2015-10
    關聯: Toxicology Letters. 2015 Oct;238(2, Suppl.):S369.
    Link to: http://dx.doi.org/10.1016/j.toxlet.2015.08.1055
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0378-4274&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000370693801885
    顯示於類別:[李立安] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000370693801885.pdf67KbAdobe PDF461檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋